secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001725160-26-000020
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis presents preclinical azenosertib data in TNBC; real-world ovarian cancer outcomes shown
--------------------------------------------------------------------------------

- Azenosertib + enfortumab vedotin induced 87.5% complete responses in ADC-resistant TNBC PDX model; 5 of 8 mice had no progression after treatment stop.
- Median PFS not reached for azenosertib+EV vs. 22 days for EV alone (HR=0.14, p<0.0001) in TOP1i-ADC-resistant model.
- Real-world data: Cyclin E1-positive ovarian cancer patients had shorter time to next treatment (13.2–14.9 months) vs. Cyclin E1-negative (19.5 months), p=0.002.
- Azenosertib monotherapy showed 42–99% tumor growth inhibition across 12 TNBC xenograft models.
- Data presented at AACR 2026; company plans to explore azenosertib combinations post-ADC in TNBC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000020/0001725160-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000020/zntl-20260417.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer